Skip to main content
. 2016 Jun 20;71(9):2642–2645. doi: 10.1093/jac/dkw203

Figure 1.

Figure 1.

Virological treatment outcome by DAA regimen (N = 54). SOF/SMV, sofosbuvir/simeprevir; SOF/RBV, sofosbuvir/ribavirin; SOF/LDV, sofosbuvir/ledipasvir; PrOD, paritaprevir/ritonavir/ombitasvir/dasabuvir. ^Four relapses; one death (SOF/SMV); one with EOT then lost to follow-up (SOF/SMV). 1Twelve weeks GT1a/1b (n = 34) and 24 weeks GT1b (n = 1). 2Twelve weeks GT2a (n = 1), 16 weeks GT2a/b (n = 3), 24 weeks GT1a (n = 2) and 24 weeks GT3 (n = 1). 3Eight weeks GT1a (n = 2), 12 weeks GT1a/1b (n = 8) and 24 weeks GT1a (n = 1). 4Twelve weeks GT1a (n = 1).